Moderna CFO Jamey Mock told Barron’s it would still be possible, despite the cuts. Mock said that while the company has cut back significantly on its capacity to put vaccine doses in vials, it ...
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...
There is no antiviral treatment for the miserable but thankfully short-lived illness, and no vaccine—yet. But scientists at Moderna are in the late stages of testing what could be the first such ...
In these cases, the label on the vaccine vial had also been falsified. The Vaccine Identify Evaluation (VIE) Collaboration are developing novel tests for detecting falsified vaccines in supply chains.
Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...
Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...
To that end, HHS has granted Moderna $590 million to help accelerate the development of a bird flu vaccine. The agency announced its backing of the Massachusetts-based pharmaceutical firm about 72 ...